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HCV is one of the most important infections
affecting prison populations in the United
States (US) and worldwide. Because incarcer-
ation is common among previous and current
injection drug users, infectious diseases, par-
ticularly HCV, are prevalent among the incar-
cerated population. Additionally, while incar-
cerated populations are at high risk for HCV
and other infectious diseases, many inmates
are not routinely screened or treated for HCV
infection, despite evidence demonstrating that
screening for HCV and other sexually trans-
mitted infections among inmates is feasible,
acceptable and efficacious.1 Because of the
high prevalence of HCV within corrections,
IDCR has decided to cover HCV in two issues
this year.  William Cassidy, MD discussed the
management of HCV infection in our July 2005
issue. This article will address HIV and HCV
co-infection, which affects an estimated
350,000 persons domestically, of which a large
proportion are incarcerated in the US correc-
tional system. 
Until recently, little data on HIV/HCV co-infec-
tion existed.  HCV infection is clearly exacer-
bated in the presence of HIV infection.4,5 The
impact of HCV infection on HIV disease pro-
gression is controversial.2,3 Interactions
between HIV and HCV medications, anemia,
antiretroviral-induced hepatotoxicity and mito-
chondrial toxicity are just some of the concerns
clinicians must address when treating co-
infected patients.  Fortunately, however, treat-
ment approaches for both diseases have
advanced dramatically over time.  Anti-HCV
treatment consideration should be given to co-
infected patients, particularly because sus-
tained virologic response (SVR) rates upwards
of 50% have been documented in co-infected
patients with once-weekly pegylated interferon
(PEG IFN) and daily ribavirin (RBV), the stan-
dard of care treatment for both HCV mono-
infection and HIV/HCV co-infection. In the
past, the maxim was to initially control HIV
infection before initiating HCV therapy.
Modern treatment options and clearer under-
tanding of the diseases’ processes have
modified that approach.
Epidemiology
Approximately 30% of patients who are infect-
ed with HIV are also infected with HCV.  While
the two viruses share similar modes of trans-
mission, transmission efficiency of each virus
differs substantially. HCV is transmitted pri-
marily by percutaneous exposure to blood.  In
the US, injection drug use is the leading route
of transmission. HCV is approximately 10
times more infectious by percutaneous blood
exposure to small volumes of blood as com-
pared to HIV.  In addition to exposure by injec-
tion drug use, HCV may also be transmitted
between sexual partners.  Because of shared
routes of transmission, HCV and HIV co-infec-
tion in the United States is common, affecting
85% to 90% of those reporting injection drug
use and 10% to 14% among persons reporting
high-risk sexual behavior.4
Data has demonstrated that HIV infection
clearly exacerbates the natural history of HCV
infection and accelerates progression to cir-
rhosis, end-stage liver disease and hepatocel-
lular carcinoma.5,6 In a recent retrospective
cohort study, the survival of 1,037 HCV mono-
infected and 180 HIV/HCV co-infected patients
after the first hepatic decompensation was
analyzed.  The survival of co-infected patients
was markedly shorter than that of mono-infect
ed patients.  Additionally, the 1-, 2- and 5-year
survival estimates where 74%, 61% and 44%,
respectively, among individuals without HIV
co-infection and 54%, 40% and 25%, respec-
tively, among co-infected patients.7 (Figure 1)
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Inmate Knowledge of HCV Status
A large proportion of inmates are unaware of their HCV status.  A
recent study found that of 121 untested or previously known to be
anti-HCV antibody negative inmates in the Australia prison sys-
tem, 25 were found to be HCV-positive. More than one-half of
those who tested positive perceived that they did not have HCV
infection, while 44% were unsure of their status.  Those inmates
who were incorrect about their HCV status were less educated
and more likely to have previously been incarcerated.8
Predicting Response to Treatment
A number of viral and host factors influence treatment response
to interferon (IFN)-based therapy in HCV mono-infected patients,
including HCV genotype, high viral load, low CD4 T-cell counts,
alcohol use, racial distribution and hepatic steatosis.  Evidence is
beginning to emerge indicating that many of these response fac-
tors, particularly genotype and high viral load, may be generalized
to co-infection.17
HCV genotype has been recognized as one of the strongest pre-
dictors of achieving a SVR.  Patients infected with HCV genotype
1 are significantly less likely to achieve a SVR, despite longer
duration and higher doses of treatment, than patients infected
with HCV genotypes 2 or 3.15,17 This is elaborated upon below in
the section entitled "Pegylated Interferon and Ribavirin - The
Data".
High viral load negatively impacts response to HCV treatment, as
does low CD4 T cell count.  A reduced likelihood of achieving a
SVR has been documented in patients with HCV viral loads
greater than 107 copies/mL and HIV CD4 counts less than 500
cells/mL.9 In one study that evaluated PEG IFN alfa-2a and RBV
in HCV mono-infected patients, persons with genotype 1 and a
high HCV viral load (>2 x 106 copies/ml) had an SVR of 41%,
whereas the SVR rate among those with genotype 1 and a low
viral load who were treated with the same regimen was 56%.
Among persons infected with HCV genotypes 2 and 3 and a high
viral load, the SVR rate was 74%, while those with genotypes 2
and 3 and a low viral load who were treated with the same regi-
men had a SVR of 81%.10 Similar evidence has shown that co-
infected patients with a high pre-treatment HIV viral load are also
less likely to achieve a SVR as compared to patients with a low
pre-treatment HIV viral load.17
Patients who achieve an early virologic response (EVR), defined
as an undetectable HCV RNA level or a decrease of 2 log or more
in HCV RNA level by week 12, are more likely to achieve a SVR.
In the APRICOT study, of patients who had an EVR by week 12,
30% of those in the group given IFN alfa-2a plus RBV, 37% of
those in the group given PEG IFN alfa-2a plus placebo and 56%
of those in the group given PEG IFN alfa-2a plus RBV, achieved
SVRs at week 72.  Patients who did not achieve an EVR at week
12 were highly unlikely to have a SVR at week 72 (Figure 2.)17
Other studies have demonstrated similar results.11
Several studies among HCV mono-infected persons have been
conducted demonstrating that SVR rates are markedly decreased
for African Americans compared to Caucasians.12,13,14Given the
high proportion of African Americans in correctional settings and
ata demonstrating reduced response rates, the correctional set-
ting provides a unique opportunity to test and treat HCV in this
population.  Studies assessing the rate of SVR to PEG IFN alfa-
2a plus RBV among HIV/HCV co-infected African American
patients compared to Caucasian patients have not been done.
Additionally, while the basis for lower response rates among HCV
mono-infected African Americans is not fully understood, it is rec-
ommended that all patients with chronic HCV, regardless of eth-
nic r racial background, receive anti-HCV therapy.15,16
Pegylated Interferon and Ribavirin - The Data
SVR rates are lower among HIV/HCV co-infected patients com-
pared to HCV mono-infected patients. However, the three trials
2
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Figure 1: Probability of Patient Survival by HIV Serostatus
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Figure 2: Early Virologic Response as a Predictor of Sustained Virologic Response
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3described below have demonstrated that SVR rates approximat-
ing 40% among co-infected patients may be achieved with PEG
IFN plus RBV treatment - the standard of care for HIV/HCV co-
infection treatment - and an even greater percentage of patients
achieve histologic improvement with this therapy, warranting
treatment of these patients.15,17
ACTG
In the AIDS Clinical Trials Group (ACTG) A5071 study, 133 co-
infected patients were randomized to receive standard IFN plus
RBV or PEG IFN alfa-2a plus RBV, achieving SVR rates of 12%
and 27%, respectively.  Among patients receiving PEG IFN alfa-
2a plus RBV, mean SVR rates differed significantly: HCV geno-
type 1-infected patients achieved a mean SVR rate of 14%, while
HCV genotype non-1-infected patients achieved a SVR rate of
73%.  Both regimens were well tolerated and neither was associ-
ated with loss of HIV disease control.  Premature discontinuation
rates were similar and low in both groups. 
RIBAVIC
In a similar, larger European study, the Randomized Controlled
Trial of Pegylated-Interferon alfa-2b plus Ribavirin vs Interferon
alfa-2b plus Ribavirin for the Initial Treatment of Chronic Hepatitis
C in HIV-co-infected patients (ANRS HC02-RIBAVIC), 416 co-
infected patients were randomized to receive standard IFN plus
RBV or PEG IFN plus RBV, achieving SVR rates similar to those
reported in the ACTG trial.  Discontinuation rates for this trial were
high, with 42% of patients discontinuing therapy early.  Episodes
of symptomatic hyperlactatemia and pancreatitis occurred in 31%
of patients.18
APRICOT
The largest study to date, the AIDS Pegasys® Ribavirin
International CO-Infection Trial (APRICOT), evaluated the effica-
cy and safety of PEG IFN alfa-2a plus RBV in 868 HIV/HCV co-
infected patients.  Patients were randomized to one of three 48-
week treatment regimens:
w Group 1:  IFN alfa-2a 3 MIU TIW plus RBV 800 mg daily;
w Group 2: PEG IFN alfa-2a 180 mcg QW plus placebo; or
w Group 3: PEG IFN alfa-2a 180 mcg QW plus RBV 
800 mg daily.
Among patients in this trial, 61% were HCV genotype-1 infected;
15% were cirrhotic.  Eighty-five percent of patients were receiving
HAART and the mean CD4 T cell count prior to therapy was 530
cells/mm3.  Overall, mean SVR rates were as follows:
w Group 1:  IFN alfa-2a 3 MIU TIW plus RBV 
800 mg daily      12%;
w Group 2: PEG IFN alfa-2a 180 mcg QW plus 
placebo      20%;
w Group 3: PEG IFN alfa-2a 180 mcg QW plus RBV 
800 mg daily      40%.
Additionally, HCV genotype 2- and 3-infected patients randomized
to group 3 achieved a mean SVR rate of 62%.  The overall SVR
of 40% among group 3 patients was the highest in any reported
study of co-infected patients thus far. (See Table 1 for SVR rates
of the three different treatment regimens.)19
Treatment
HCV treatment is feasible and effective within corrections.  A ret-
rospective study of 80 inmates who had received anti-HCV treat-
ment found that adherence to therapy was high.  Nearly 80% of
inmates completed treatment; 66.3% achieved a SVR.20 A simi-
lar study of 90 male inmates who had received anti-HCV treat-
ment found that adherence to therapy approximated 80%; overall
SVR was 55.9%.  Furthermore, SVR rates for HCV genotype 1-,
2- and 3-infected persons were 31.6%, 100% and 71.4%, respec-
tively.21
The American Association for the Study of Liver Disease (AASLD)
recommendations for the management of HCV in HIV-infected
persons include the following:22
w Anti-HCV testing should be performed in all HIV-infected 
persons;
w HCV RNA testing should be performed to confirm HCV 
infection in HIV-infected persons who are positive for anti-
HCV, as well as those who are negative and have evidence 
of unexplained liver disease;
w HCV should be treated in the co-infected person in whom 
the likelihood of serious liver disease and a treatment 
response are judged to outweigh the risk of morbidity from 
the adverse effects of therapy;
w Initial treatment of HCV in most HIV-infected persons is 
PEG IFN plus RBV for 48 weeks;
w Given the high likelihood of adverse events, HIV/HCV 
co-infected persons on HCV treatment should be monitored 
closely;
w RBV should be used with caution in persons with limited 
myeloid reserves and in those taking zidovudine (ZDV) and 
stavudine (d4T). When possible, patients receiving 
didanosine (ddI) should be switched to an equivalent 
antiretroviral before beginning therapy with RBV;
w HIV-infected patients with decompensated liver disease 
may be candidates for orthotopic liver transplantation.
Currently, the only Food and Drug Administration (FDA)-approved
treatment for co-infected patients who have compensated liver
disease and have not previously been treated with IFN alfa is
PEG IFN alfa-2a (Pegasys®, Hoffman-La Roche) in combination
with RBV (Copegus®, Hoffman-La Roche), both of which were
approved for HCV therapy in co-infected patients in February
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Table 1: SVR Rates Obtained in APRICOT Study
Figure adapted from Pineda J, et al.
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2005.23 Pegasys® is dosed at 180mcg as a subcutaneous injec-
tion given once weekly.  Copegus® is available as a 200mg tablet
and is administered orally twice daily as a split dose.  The most
common adverse events reported for this combination therapy
include fatigue, headache, pyrexia, myalgia, anxiety, insomnia,
alopecia, neutropenia and nausea.  Pegasys® is contraindicated
in patients who have hepatic decompensation (Child-Pugh score
greater than 6.)  Copegus® is contraindicated in women who are
pregnant.  Women of childbearing potential should have a preg-
nancy test before initiation of therapy with Copegus®.24,25
Optimal treatment duration and dosing of both PEG IFN and RBV
may need to be adjusted on a case-by-case basis.  In contrast to
HCV genotype 2- and 3-mono-infected patients who are treated
adequately with PEG IFN alfa-2a plus RBV 800 mg/day for 24
weeks26, HIV/HCV genotype 2- and 3-co-infected patients should
be treated with PEG IFN alfa-2a 180mcg plus RBV 800-1,200mg
day for 48 weeks.27 Both HCV genotype 1 mono-infected patients
and HIV/HCV genotype 1 co-infected patients benefit from 48
weeks of treatment with PEG IFN alfa-2a 180 mcg plus RBV
1,000-1,2000 mg/day.22,23
There are several safety concerns that must be considered when
treating the co-infected patient.  RBV-associated anemia may be
of greater concern in co-infected patients than in HIV mono-infect-
ed patients because of the high prevalence of pre-existing anemia.
Clinicians should monitor for anemia.  Treatment of patients who
become anemic during PEG IFN/RBV therapy with erythropoietin
alfa may represent an alternative to RBV dose reduction or dis-
continuation, both of which lower treatment efficacy.28 Strategies
aimed at optimizing doses and adherence to RBV might help to
improve responses to HCV therapy in co-infected patients.29
The risk of hepatotoxicity associated with different HAART regi-
mens in co-infected patients has not been well elucidated. The risk
of HAART-induced hepatotoxicity is greater in co-infected patients
than in mono-infected patients, but controversy exists regarding
what factors influence this phenomenon. The nucleoside reverse
transcriptase inhibitor (NRTI), ddI, is contraindicated in patients
receiving anti-HCV therapy due to an increased risk of hepatotox-
icity, lactatemia, pancreatitis and mitochondrial toxicity.30
Additionally, the non-nucleoside reverse transcriptase inhibitor
(NNRTI), nevirapine (NVP), and the protease inhibitor (PI), riton-
avir (RTV), may increase the risk of transaminase elevation in co-
infected patients.31 Frequency of laboratory monitoring should be
increased in persons with risk factors for hepatotoxicity, especially
in those with pre-existing liver disease.
Concern regarding the concomitant administration of PEG IFN,
RBV and anti-HIV medications exists.  There is increasing concern
that d4T may be linked with steatosis in patients receiving anti-
HCV therapy.32 Anemia is a frequently seen side effect of RBV.
AZT in combination with RBV has a synergistic effect on anemia,
warranting careful monitoring of patients receiving these two med-
ications in combination.  Lastly, abacavir (ABC) dosage may need
to be reduced in cirrhotic patients.
Conclusion
HIV/HCV co-infection among injection drug users is prevalent.
Because of the synergism between injection drug use and incar-
ceration, all inmates should be screened, and when appropriate,
treated, for HIV and HCV infections. The Infectious Diseases
Society of America (IDSA) and the AASLD guidelines for the man-
agement of HCV recommend that patients co-infected with HIV
and HCV undergo medical evaluation for HCV-related liver dis-
ease and consideration for HCV treatment and, if indicated, liver
transplantation.  The same standard of care should apply to incar-
cerated populations.  Because of the accelerated disease course
HCV takes in the presence of HIV, treatment of HCV in co-infect-
ed persons is critical.  Indeed, it may take priority over HIV treat-
ment. Individualizing the patients' treatment regimen is essential
and depends on many factors including medical and psychiatric
co-morbidities, liver status, antiretroviral therapy, possible effects
of reconstitution of the immune system and length of incarceration,
in determining which entity to treat first or in selecting simultane-
ous treatment. Nonetheless, recently completed randomized con-
trolled trials provide evidence of the safety, tolerability and efficacy
of HCV treatment with PEG IFN-alfa plus RBV in HIV-infected
individuals.
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Dear Colleagues, 
HIV/Hepatitis C virus (HCV) co-infection is commonly seen in the correctional environment. In
fact, prisons and jails are probably the greatest single repository of patients co-infected with
these viruses.  This month's main article focuses on the epidemiology, treatment and control of
HIV/HCV co-infection. 
The algorithm deals with another aspect of correctional healthcare - control of hepatitis B virus
(HBV). One of the most challenging tasks we face during any outbreak is ensuring that all
inmates are screened, receive prophylaxis and appropriate follow-up.  The February issue of
IDCR noted this challenge in a tuberculosis outbreak in a state prison. The problems with hepati-
tis viruses and corrections are well discussed in a Bureau of Justice Statistics article by Allen
Beck and Laura Maruschak1 as well as two recently published Monthly Morbidity and Mortality
Reports (MMWR) on specific HBV outbreaks within correctional facilities.2,3
In 2003, Centers for Disease Control and Prevention re-iterated its' 1992 stance that all inmates
in all correctional systems should be vaccinated for Hepatitis A Virus (HAV) and HBV.4 It is most
unfortunate that, for economic reasons, many systems do not accomplish this. It is possible that
within our lifetime we could eradicate these infectious diseases. The combination of the school-
children vaccine program and universal correctional vaccination could lead to the virtual eradi-
cation of HAV and HBV.
After reading this issue, you should be familiar with the distinctions between HCV mono-infec-
tion and HIV/HCV co-infection and should also be familiar with HBV and HCV treatment options.
All of us who work in corrections need to understand our role in the larger public health and
advocate for the seamless continuity of care for our patients. Public health and correctional
healthcare are determinants of public safety and should be of utmost importance to us all.
Very truly yours,
David Thomas*, MD
*Nothing to disclose
1. Beck A, Maruschak, L.  BJS.  2004; NCJ 199173?C.
2. CDC.  MMWR.  2004; 53(30):678-81.
3. CDC.  MMWR.  2001; 50(25):529-32.
4. CDC.  MMWR.   2003; 52(RR01):34-6.
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CASE STUDY: Chronic Hepatitis B and D in a Patient Co-infected with HIV
Q: What tests should you order today?
A: HIV-1 quantitative viral load, HBV quantitative viral load, HDV
antibody, hepatitis B e antigen (HBeAg), hepatitis A antibody, liver
function tests (LFTs), metabolic panel with electrolytes, creatinine,
CBC and RPR would all be relevant and important tests to con-
sider given this inmates’ history and physical exam findings sug-
gestive of possible early cirrhosis with scleral icterus.  He also
needs a serum alpha- fetoprotein (AFP) level and abdominal ultra-
sound to screen for cirrhosis and hepatocellular carcinoma (HCC).
His tests show a detectable HIV-1 viral load of 1,000 copies/mL,
CD4 count 336 (40%), HBV viral load of 220,000 copies/mL, pos-
itive hepatitis D antibody and hepatitis B e antigen, negative
hepatitis A antibody, abnormal LFTs with an AST of 90, ALT of 97,
total bilirubin 1.9, albumin 3.3, BUN 9, creatinine 0.5, sodium 134
and other electrolytes normal, WBC 4.8, H/H 15/44, platelet count
64k and non-reactive RPR.  AFP level is elevated at 27.8 ng/ml
with ultrasound showing (1) nodular and coarsened liver consis-
tent with cirrhosis, and (2) evidence of portal hypertension includ-
ing marked splenomegaly and gallbladder wall thickening.  
Based on these findings, you conclude the inmate has chronic per-
sistent HBV and HDV with cirrhosis secondary to this.  Though his
ultrasound does not show evidence of HCC, he remains at high
risk for this and should be rescreened with ultrasound and AFP at
regular intervals (ie - every six-12 months).  Chronic HBV carriers
who are both hepatitis B surface and e antigen positive are at high-
est risk for HCC (at least 100 times higher than that for non-carri-
ers). You also offer him the HAV vaccine since he is not immune
and is at high risk for acquisition with potential for worsening liver
disease.
Q: Are his current medications adequate?  If not, what med-
ication changes should be considered and why?
A: His HIV and hepatitis medications do not appear to be control-
ling his infections due to detectable viral loads and evidence of
advanced liver disease, though he admits to non-compliance. He
should be continued on his current medications until you are able
to get an HIV genotype resistance assay. There are several issues
to consider in this co-infected patient. Even if his HIV is resistant
to 3TC, withdrawal of it might precipitate worsening liver disease.
D4T and nevirapine may be contributing to his liver disease/ele-
vated enzymes and should be changed to a different antiretroviral
with activity against HBV. In general, avoidance of DDI, d4T (the
so-called "D drugs"), nevirapine and some of the protease
inhibitors, such as ritonavir, in co-infected patients is prudent due
to risk of liver toxicity.  Other options to treat the HBV and HIV
infections may be tenofovir, though this is not yet FDA-approved
for the treatment of HBV, entecavir, which has been shown to be
more active against HBV than adefovir, (recently approved by the
Food and Drug Administration in March, 2005) or adefovir.
Truvada® and Emtriva® are two co-formulations that also have
activity against HBV and reduce pill burden by one. Combination
therapy with 3TC and another anti-HBV agent, such as entecavir,
should decrease his HBV viral load and reduce liver inflammation.
Combination therapy may reduce risk of HBV resistance, though
there is not much data to support this yet. Finding a regimen that
has activity against HIV and HBV is optimal for the patient to
reduce pill burden. However, only adefovir is FDA-approved for
use in both HIV and chronic HBV, but is associated with significant
nephrotoxicity if given in higher doses necessary to treat HIV.
Another course of IFN therapy will not be of benefit to him since he
already failed a year of therapy with progression of disease post-
therapy.  
HIV genotype is sent and shows no resistant mutations. Due to the
high HBV viral load and risk of liver toxicity from d4T and nevirap-
ine, you switch him to tenofovir, 3TC and Sustiva®. His HBV and
HIV viral load, T cell count, LFTs and HBeAg should be monitored
on therapy (ie - every three months). 
Discussion
The primary goals of therapy for chronic HBV infection are to
reduce viral load burden and treat hepatic dysfunction in an effort
to prevent cirrhosis and HCC. There are clear indications for ther-
apy in HBeAg-positive patients since they are at highest risk for
early progression to chronic active hepatitis, cirrhosis and HCC.
After treatment is initiated, markers of success include improve-
ment in liver function, reduction in viral load, loss of HBeAg and
seroconversion to anti-HBe antibodies. Loss of HBsAg and disap-
p arance of viremia occur infrequently (1 to 5% of patients).  
In 2004, recommendations from a consensus conference on HIV
and chronic hepatitis due to HBV and HCV were published.  In the
report, the expert panel summarizes several important recommen-
d tions, based on findings from the literature: (1) HIV infection
enhances viral replication in patients co-infected with HBV.
HBeAg-positive chronic HBV is more common in those with HIV
and liver disease may be more severe with more rapid progression
By Bethany Weaver*, D.O., M.P.H., Acting Instructor of Medicine, University of Washington Center for AIDS & STD Research
*Nothing to disclose
CASE: A 44 year-old Caucasian inmate presents to intake clinic for clinical evaluation as he begins his three-year sentence.  He has
a history of asymptomatic HIV infection since 1989 and is taking d4T, 3TC and nevirapine, though he reports he misses doses about
once per week and is only taking nevirapine 200 mg po qd as he is concerned about liver toxicity.  He has chronic active hepatitis B
virus (HBV) and hepatitis D virus (HDV) co-infection since at least 1990 and was treated with interferon (IFN) therapy without
response for one year in 1995.  He has sex with men and uses crystal methamphetamine intermittently. He denies any alcohol use for
the last five years but admits to heavy consumption for 10 years prior to this.  He is complaining only of fatigue and occasional nau-
sea/vomiting but denies hematemesis.  He has been out of care recently due to drug use and thinks his liver enzymes were higher
than usual when his doctor last saw him approximately four months ago. On physical exam, he weighs 140 pounds, blood pressure is
132/91, pulse is 89, temperature is 37 and respirations are 16.  He appears thin with some temporal wasting, mild scleral icterus, no
oral thrush, no lymphadenopathy, clear chest, normal cardiac exam, abdomen benign with no hepatosplenomegaly or
distension/ascites appreciated, extremities without edema and skin normal.
(continued on page 7)
7IDCR-O-GRAM: Treatment of Chronic Hepatitis B Virus
HBeAg status Positive
HBV DNA <105 >105 >105
(copies/mL)
ALT Level Normal Normal Elevated
Treatment No treatment Consider biopsy; Treat with adefovir, 
Strategy Monitor every treat if disease with 3TC or IFN*  
6-12 months 3TC or adefovir*
HBeAg status Negative
HBV DNA <104 >104 >104
(copies/mL)
ALT Level Normal Normal Elevated
Treatment No treatment Consider biopsy; Long-term treatment 
Strategy Monitor every treat if disease required*
6-12 months
HBeAg-Positive Patients:Patients should be treated after HBeAg seroconversion until HBV DNA levels are undetectable.
Treatment then should be continued for an additional six months.  In patients who have HBeAg seroconversion, but in whom HBV
DNA levels remain detectable, treatment should continue for six months.  Seroconversion should be documented again, then treat-
ment discontinuation should be considered.  Patients who relapse can be re-treated.  Adefovir should be considered for long-term use
in patients who were initially treated with 3TC because of a decreased risk of resistance development. 
HBeAg-Negative Patients:HBeAg-negative patients tend to have lower serum HBV DNA levels than HBeAg-positive patients, but
may still have disease.  Recommendations are similar to those for HBeAg-positive patients.  
*Entecavir, though not yet in the guidelines developed by Keefe E, et al, will likely appear in the next revision of guidelines.  Entecavir
has the best resistance profile when compared to other anti-HBV medications.
Adapted from Keefe E, et al.  Clin Gastroenterol Hepa.  2004; 2:87-106.
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to cirrhosis (BII recommendation); (2) Patients with HIV/chronic
HBV, as opposed to HIV alone, are more prone to develop elevat-
ed LFTs after initiating antiretroviral therapy (BIII recommenda-
tion); (3) Chronic HBV may accelerate HIV disease progression in
patients co-infected with both infections (CII recommendation); (4)
Treatment should be considered in all patients with HIV/chronic
HBV with HBsAg-positivity, detectable HBV DNA and elevated
LFTs.  For patients who are on or who need treatment for HIV,
3TC, tenofovir or both should be considered as first choice.  IFN
may be considered for those patients who do not need HIV treat-
ment yet but require HBV treatment (BII recommendation); (5) All
HIV-infected patients with end-stage liver disease should be con-
sidered as candidates for liver transplantation as long as they do
not have advanced HIV disease and have abstained from alcohol
and illegal drugs for at least six months (BII recommendation).
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8HBV 101: Recommended Post-Exposure Prophylaxis for Exposure to Hepatitis B Virus
Vaccination Treatment
and antibody Source
response status of Source Source unknown or not
exposed workers*    HBsAg† positive HBsAg† negative  available for testing
Unvaccinated HBIG§ x 1 and initiate  Initiate HB vaccine   Initiate HB vaccine
HB vaccine series       series^ series
Previously vaccinated
Known responder**  No treatment No treatment No treatment
Known HBIG x 1 and initiate    No treatment If known high risk
Nonresponder†† revaccination source, treat as
or HBIG x 2^^ if source were HBsAg
positive
Antibody response Test exposed person   No treatment Text exposed person
unknown for anti-HBs§§ for anti-HBs
1.  If adequate, no 1. If adequate, no
treatment is treatment is
necessary necessary
2.  If inadequate, 2. If inadequate,
administer administer vaccine
HBIG x 1 and booster and
vaccine booster recheck titer in 
1-2 months
*Persons who have previously been infected with HBV are immune to re-infection and do not require post-exposure prophylaxis
†Hepatitis B surface antigen
§Hepatitis B immune globulin; dose is 0.06mL/kg intramuscularly
^Hepatitis B vaccine
**A responder is a person with adequate levels of serum antibody to HBsAg (i.e., anti-HBs > 10 mIU/mL)
††A nonresponder is a person with inadequate response to vaccination (i.e., serum anti-HBs < 10 mIU/mL)
^^The option of giving one dose of HBIG and re-initiating the vaccine series is preferred for non-responders who have not completed
a second 3-dose vaccine series.  For persons who previously completed a second vaccine series but failed to respond, two doses of
HBIG are preferred.
§§Antibody to HBsAg
Editors Note:Correctional healthcare workers SHOULD ALWAYS be vaccinated against HBV.1
High-risk groups for whom vaccination is recommended include: 
1. Persons with occupational risk. HBV infection is an occupational hazard for health care workers and for public-safety workers who
have exposure to blood in the workplace. The risk of acquiring HBV infections from occupational exposures depends on the frequency
of percutaneous and permucosal exposure to blood or blood-contaminated body fluids. Any health care or public safety worker may
be at risk for HBV exposure, depending on the tasks he or she performs. Workers who perform tasks involving contact with blood or
blood-contaminated body fluid should be vaccinated. For public safety workers whose exposure to blood is infrequent, timely post-
exposure prophylaxis should be considered rather than routine pre-exposure vaccination.2
Adapted from CDC.  MMWR.  2001; 50(RR11):1-42.
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Name (Abbreviation)
Hepatitis B Surface 
Antigen (HBsAg)
Hepatitis B Surface 
Antibody (Anti-HBs)
Total Hepatitis B Core
Antibody (Anti-HBC)
IgM Antibody to
Hepatitis B Core
Antigen (IgM anti-HBc)
Definition
Serologic marker on the surface of HBV.  It can be detected in high levels in serum during acute or chronic
infection. The presence of HBsAg indicates that the person is infectious. The body normally produces anti-
bodies to HBsAg as part of the normal immune response to infection.
The presence of anti-HBs is generally interpreted as indicative of recovery and immunity from HBV infec-
tion. Anti-HBs also develops in a person who has been successfully vaccinated against HBV.
Appears at the onset of symptoms in acute hepatitis B virus and persists for life.  The presence of anti-HBc
indicates previously or ongoing HBV infection.
This antibody appears during acute or recent HBV infection and is present for approximately six months.
HBV101: Hepatitis B Definitions
Table adapted from CDC.  Viral Hepatitis B.  Last accessed September 27, 2005 from http://www.cdc.gov/ncidod/diseases/hepatitis/b/Bserology.htm
"Drug-drug Interactions and
Metabolic Complications of
HIV"
Satellite Broadcast
October 26, 2005
12:30-2:30pm EST
Visit: www.amc.edu/patient/hiv/
hivconf/index.htm
8th Annual Symposium of
Controversies in the
Management of the HIV-
Infected Patient
New York City, NY
November 4, 2005
Call: 212.746.4177
2005 International Drug Policy
Reform Conference
Long Beach, CA
November 10-12, 2005
Visit: www.drugpolicy.org/events/
dpa2005/
New England Regional
Conference on HIV Treatment &
Prevention
November 11, 2005
Visit: www.searchforacure.org
American Association for the
Study of Liver Diseases
Meeting
November 11-15, 2005
San Francisco, CA
Visit: www.aasld.org
Update in the Care of HIV
Infection
November 30, 2005
Pittsburgh, PA
Call: 412.359.4952
National Viral Hepatitis
Prevention Conference
December 5-9
Washington, DC
Visit: www.signup4.net/Public/
ap.aspx?EID=2004101E
APHA Meeting and Exposition
December 10-14, 2005
Philadelphia, PA
Visit:  www.apha.org
Updates in Correctional Health
Care
April 8-11, 2005
Las Vegas, NV
Visit: www.ncchc.org
XVI International AIDS
Conference 
August 13-18, 2006
Toronto, Canada 
Visit: www.aids2006.org
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DATES
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2nd Annual Stephen Tabet Award Awarded
at NCCHC
The second annual Stephen Tabet award was
given to Becky Stephenson on October 8, 2005
at the National Conference on Correctional
Healthcare in Denver, Colorado. Dr.
Stephenson is a tireless advocate for the
enhancement of healthcare for the incarcerated.
She is a dedicated clinician, is universally loved
by her staff and her patients and leads a highly
successful HIV program. All of us at IDCR
believe that Dr. Tabet would be proud of this
wonderful clinician being recognized as the sec-
ond recipient of this award.
New HIV Drug Effective, Needs Evaluation
The emergence of drug-resistant HIV-1 mutants
often results in treatment failure.  Baba, et al
recently conducted a study to examine the anti-
HIV-1 activity and resistance profile of 2'-3'-
didehydro-3'-deoxy-4'-ethynylthymidine (4'-
Ed4T), a nucleoside analog that is structurally
similar to d4T.  When 4'-Ed4T, d4T and 3TC
were examined for their inhibitory effects on
HIV-1 replication, 4'-Ed4T was found to be the
most active among the three compounds; 4'-
Ed4T was approximately four times more potent
than d4T.  Additionally, the anti-HIV-1 activity of
4'-Ed4T was not affected by the K65R mutation
and the multi-drug-resistant mutation Q151M
complex.  The authors concluded that 4'-Ed4T
is a potent and selective inhibitor of HIV-1 repli-
cation and is less cytotoxic to host cells than
d4T in vitro. 4'-Ed4T also shows a unique resis-
tance drug profile that differs from that of known
NRTIs, warranting further evaluation of its
potential as an anti-HIV-1 agent.
Baba M, et al.  Antimicrobial Agents and
Chemotherapy.  2005; 49(8):3355-60.
Is HBV Genotype a Predictor of Treatment
Response?
Erhardt, et al retrospectively analyzed 165 HBV-
infected patients to determine if genotype is a
predictor of treatment response.  Of patients
investigated, 47.3% and 40.0% were HBV
genotype A- and D-infected, respectively.
Patients infected with HBV genotypes C, B, E
and G comprised a small percentage of total
patients analyzed. Overall sustained virologic
response (SVR) rate to IFN therapy six months
post-treatment was 35%. SVR rates differed
dramatically between HBV genotype A and D.
Of HBV genotype A- and D-infected patients,
49% and 26%, respectively, achieved a SVR at
six months post-treatment. Furthermore, SVR
rates at 12 months post-treatment were 47% for
HBV genotype A-infected patients compared
with 23% for HBV genotype D-infected patients.
Erhardt, et al concluded that response to IFN
t erapy is HBV genotype dependent.
Erhardt A, et al.  Gut.  2005; 54:1009-13.
Effective Treatment for Chronic HBV
A recent study sought to determine the efficacy
of PEG IFN alfa-2a plus lamivudine (3TC), PEG
IFN alfa-2a without 3TC and 3TC monotherapy
for the treatment of hepatitis B e antigen
(HBeAg)-positive chronic HBV.  Eight hundred
fourteen patients with HBeAg-positive chronic
HBV received either 180ug PEG IFN alfa-2a
once weekly plus 100mg oral 3TC daily, 180ug
PEG IFN alfa-2a monotherapy once weekly, or
3TC monotherapy, for 48 weeks. All patients
were followed for an additional 24 weeks, for a
total of 72 weeks.  At the end of treatment (week
48), HBeAg seroconversion occurred in 24%,
27% and 20% of patients receiving PEG IFN
alfa-2a plus 3TC, PEG IFN alfa-2a monothera-
py and 3TC monotherapy, respectively.  At the
end of follow-up (week 72), HBeAg seroconver-
sion remained highest among patients treated
with PEG IFN alfa-2a monotherapy.  Virologic
response at week 48 was greatest among
patients receiving combination therapy.  At
week 72, suppression of HBV DNA levels to
less than 100,000 copies/ml occurred in 32%,
34% and 22% of patients receiving PEG IFN
alfa-2a plus 3TC, PEG IFN alfa-2a monothera-
py and 3TC monotherapy, respectively.  Study
authors concluded that in patients with HBeAg-
positive chronic HBV, PEG IFN alfa-2a is more
efficacious than 3TC.
Lau G, et al.  New Eng J Med.  2005; 352:2682-
95.
NEWS AND LITERATURE REVIEWS
RESOURCES
Hepatitis B Information
http://www.hivandhepatitis.com/hep_b.html
HIV/HCV Co-infection Information
http://www.aidsmaps.com/en/news/9E83F736-6D3A-4789-BD09-08960CEDC664.asp
CDC. Hepatitis in Corrections information
http://www.cdc.gov/nchstp/od/cccwg/ID_Hepatitis.htm
CDC. Prevention and control of infections with hepatitis viruses in correctional settings 
MMWR.  2003; 52(RR-1):1-44.
The Hepatitis B Foundation
www.hepb.org
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SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
Brown Medical School designates this educational activity for one hour in category one credit toward the AMA Physician’s Recognition
Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through March 31, 2006. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1.  Approximately what number of persons in the United States
are co-infected with HIV and Hepatitis C Virus?
a. 250,000
b. 500,000
c. 750,000
d. 1,000,000
2. The following factors have been demonstrated to influence
treatment response to IFN-based therapy in co-infected patients:
a. HCV genotype
b. High viral load
c. Racial distribution
d. a and b
e. a, b and c
f. None of the above
3.  HCV genotype-1 infected patients have the greatest likelihood
of achieving a SVR with anti-HCV therapy.  True or False?
a. True
b. False
4.  The following statements regarding HCV treatment in co-
infected patients is/are true:
a. Treatment duration and dosing of PEG IFN plus RBV 
should be adjusted on a case-by-case basis.
b. There are two FDA-approved treatments for HCV infection 
in co-infected patients.
c. Initial treatment of HCV in most co-infected persons is 
PEG IFN plus RBV for 24 weeks.
d. a and c
e. a, b, and c
f.  None of the above
5.  Persons who have previously been infected with HBV are not
immune to re-infection and hence, require post-exposure prophy-
laxis upon exposure to HBV.  True or False?
a. True
b. False
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IDCR EVALUATION
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
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2. Do you feel that IDCR helps you in your work?
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